Boothbay Fund Management LLC Has $3.37 Million Stock Position in LivaNova PLC (NASDAQ:LIVN)

Boothbay Fund Management LLC decreased its position in LivaNova PLC (NASDAQ:LIVN - Free Report) by 25.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 72,741 shares of the company's stock after selling 24,737 shares during the quarter. Boothbay Fund Management LLC owned 0.13% of LivaNova worth $3,369,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Russell Investments Group Ltd. increased its stake in LivaNova by 17.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock valued at $70,000 after purchasing an additional 219 shares during the last quarter. Sterling Capital Management LLC grew its position in shares of LivaNova by 800.6% during the 4th quarter. Sterling Capital Management LLC now owns 1,621 shares of the company's stock valued at $75,000 after buying an additional 1,441 shares during the last quarter. Central Pacific Bank Trust Division raised its stake in LivaNova by 21.2% during the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company's stock worth $191,000 after acquiring an additional 720 shares during the period. Sanctuary Advisors LLC bought a new position in LivaNova in the third quarter worth about $219,000. Finally, Vestcor Inc acquired a new position in LivaNova in the fourth quarter valued at approximately $204,000. 97.64% of the stock is currently owned by institutional investors.

LivaNova Price Performance

Shares of LivaNova stock traded down $0.21 on Thursday, hitting $36.79. The company had a trading volume of 679,795 shares, compared to its average volume of 621,770. LivaNova PLC has a 52 week low of $32.48 and a 52 week high of $64.48. The company has a market cap of $2.00 billion, a PE ratio of 87.60 and a beta of 0.90. The business has a 50-day simple moving average of $38.33 and a 200-day simple moving average of $45.87. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87.

Wall Street Analyst Weigh In

LIVN has been the topic of several recent research reports. Stifel Nicolaus cut their price target on LivaNova from $72.00 to $60.00 and set a "buy" rating on the stock in a report on Wednesday, February 26th. Needham & Company LLC restated a "buy" rating and set a $64.00 price target on shares of LivaNova in a research report on Monday, March 17th. Barclays cut their price objective on shares of LivaNova from $58.00 to $56.00 and set an "equal weight" rating on the stock in a research report on Friday, March 7th. Mizuho decreased their target price on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a research report on Wednesday, February 26th. Finally, The Goldman Sachs Group cut their price target on LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a report on Monday, March 3rd. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $61.17.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.